DaVita Inc. $DVA Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its holdings in DaVita Inc. (NYSE:DVA) by 14.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,407 shares of the company’s stock after selling 6,923 shares during the quarter. Principal Financial Group Inc. owned about 0.06% of DaVita worth $5,369,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Man Group plc grew its stake in shares of DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares during the last quarter. Norges Bank purchased a new stake in DaVita during the 2nd quarter worth approximately $32,986,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of DaVita in the second quarter worth $21,554,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of DaVita by 132.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after buying an additional 150,318 shares during the period. Finally, Rakuten Investment Management Inc. purchased a new stake in shares of DaVita during the third quarter valued at $19,875,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on DVA shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. UBS Group increased their price target on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Barclays lifted their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, TD Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $160.50.

DaVita Price Performance

Shares of NYSE DVA opened at $149.12 on Friday. The stock has a market capitalization of $9.96 billion, a price-to-earnings ratio of 15.05, a PEG ratio of 0.52 and a beta of 0.99. The firm’s 50 day simple moving average is $117.71 and its 200-day simple moving average is $124.88. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $159.27.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.